Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

被引：146

作者：

Dufour, Jean-Francois ^{[1
,2
]}

Caussy, Cyrielle ^{[3
,4
]}

Loomba, Rohit ^{[5
]}

机构：

[1] Univ Bern, Dept Clin Res, Hepatol, CH-3010 Bern, Switzerland

[2] Inselspital Bern, Univ Clin Visceral Surg & Med, Bern, Switzerland

[3] Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud Endocrinol Diabete & Nutr, Lyon, France

[4] Univ Calif San Diego, NAFLD Res Ctr, La Jolla, CA 92093 USA

[5] Univ Calif San Diego, NAFLD Res Ctr, Dept Med, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA

来源：

GUT | 2020年 / 69卷 / 10期

基金：

瑞士国家科学基金会;

关键词：

nonalcoholic steatohepatitis; hepatobiliary disease; liver; FATTY LIVER-DISEASE; TYPE-2; DIABETES-MELLITUS; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR OUTCOMES; INSULIN-RESISTANCE; ADVANCED FIBROSIS; HIGH PREVALENCE; OBESE-PATIENTS; PLACEBO; ASSOCIATION;

D O I：

10.1136/gutjnl-2019-319104

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

引用

页码：1877 / 1884

页数：8

共 50 条

[31] Diagnosis of non-alcoholic steatohepatitis
James, OFW
STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39
[32] News on non-alcoholic steatohepatitis
Roeb, E.
Nitschmann, S.
INTERNIST, 2022, 63 (02): : 238 - 242
[33] Non-alcoholic steatohepatitis (NASH)
Michael F. Sorrell
Sandeep Mukherjee
Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
[34] Metformin in non-alcoholic steatohepatitis
Urso, R
Visco-Comandini, U
LANCET, 2002, 359 (9303): : 355 - 356
[35] Statins in Non-alcoholic Steatohepatitis
Torres-Pena, Jose D.
Martin-Piedra, Laura
Fuentes-Jimenez, Francisco
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
[36] Non-alcoholic Steatohepatitis: An Overview
Shifflet, Allison
Wu, George Y.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2009, 108 (01) : 4 - 12
[37] Non-alcoholic steatohepatitis in children
Nanda, K
PEDIATRIC TRANSPLANTATION, 2004, 8 (06) : 613 - 618
[38] Familial non-alcoholic steatohepatitis
Neuman, M. G.
Brown, M.
Cameron, R. G.
Blendis, L. M.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (06) : 221A - 221A
[39] Cannabis and non-alcoholic steatohepatitis
Cohen, L. B.
Neuman, M. G.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 51 - 51
[40] Non-Alcoholic Steatohepatitis Preface
Harrison, Stephen A.
CLINICS IN LIVER DISEASE, 2009, 13 (04) : XIII - XIV

← 1 2 3 4 5 →